Estrogen-progestogen therapy for low bone mineral density in primary biliary cirrhosis.
OBJECTIVE
Patients with primary biliary cirrhosis (PBC) often have osteoporosis of the high-turnover type, suggesting that estrogen could have a beneficial effect. However, the cholestatic potential of estrogen could imply a risk of increased cholestasis in a disease characterized by cholestasis. The aim of the present study was to test whether hormone replacement therapy (HRT) could be used to increase bone mineral density (BMD) in PBC patients with osteoporosis, without causing deterioration of the liver function.


METHODS
Nine female PBC patients with osteoporosis and one with osteopenia were offered HRT for two years. The change in BMD was compared to the change in ten age-matched female PBC patients who had less severe or no osteopenia and who did not receive HRT. Liver function tests were checked at six-month intervals.


RESULTS
HRT patients showed a statistically significant increase in lumbar spine BMD and total body BMD whereas control patients showed a significant decrease in lumbar and total body BMD. In contrast to the controls, HRT patients also showed a decrease in truncal fat (-3.8%). Neither of the groups showed any statistically significant changes in the liver function tests.


CONCLUSIONS
HRT is safe and effective in female PBC patients with osteoporosis.
Olsson
R
R
Department of Internal Medicine, Sahlgrenska University Hospital, Göteborg, Sweden.
Mattsson
L A
LA
Obrant
K
K
Mellström
D
D
D015502:Absorptiometry, Photon; D000368:Aged; D015519:Bone Density / Q000187:drug effects*; D004717:Endometrium / Q000187:drug effects; D004958:Estradiol / Q000627:therapeutic use*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects; D005260:Female; D006801:Humans; D008105:Liver Cirrhosis, Biliary / Q000150:complications*; D008111:Liver Function Tests; D008159:Lumbar Vertebrae / Q000000981:diagnostic imaging; D008525:Medroxyprogesterone / Q000627:therapeutic use*; D008875:Middle Aged; D010024:Osteoporosis / Q000150:complications / Q000517:prevention & control*; D017698:Postmenopause; D013997:Time Factors
D004958:Estradiol; D008525:Medroxyprogesterone